Risk of Alopecia Areata with Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss

    Mohit Sodhi, Ramin Rezaeianzadeh, Abbas Kezouh, Connor Frey, Mahyar Etminan
    New to Alopecia Areata? There is a guide in the encyclopedia. Read the guide →
    Image

    Preprint — not peer reviewed. This was posted to a preprint server or data repository. It has not been through a journal's review process, and its findings may change or not hold up.

    Studysummary This study observed an increased risk of alopecia areata among new users of GLP-1 agonists semaglutide and liraglutide compared to users of bupropion-naltrexone, highlighting potential hair loss concerns with these medications.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Discuss this study in the Community →